Show simple item record

dc.contributor.authorWatts, GJ
dc.contributor.authorClark, K
dc.contributor.authorAgar, M
dc.contributor.authorDavidson, PM
dc.contributor.authorMcDonald, C
dc.contributor.authorLam, LT
dc.contributor.authorSajkov, D
dc.contributor.authorMcCaffrey, N
dc.contributor.authorDoogue, M
dc.contributor.authorAbernethy, AP
dc.contributor.authorCurrow, DC
dc.date.accessioned2020-12-22T03:04:37Z
dc.date.available2020-12-22T03:04:37Z
dc.date.issued2016-01-01
dc.identifierpii: bmjopen-2016-013177
dc.identifier.citationWatts, G. J., Clark, K., Agar, M., Davidson, P. M., McDonald, C., Lam, L. T., Sajkov, D., McCaffrey, N., Doogue, M., Abernethy, A. P. & Currow, D. C. (2016). Study protocol: a phase III randomised, double-blind, parallel arm, stratified, block randomised, placebo-controlled trial investigating the clinical effect and cost-effectiveness of sertraline for the palliative relief of breathlessness in people with chronic breathlessness. BMJ OPEN, 6 (11), https://doi.org/10.1136/bmjopen-2016-013177.
dc.identifier.issn2044-6055
dc.identifier.urihttp://hdl.handle.net/11343/257773
dc.description.abstractINTRODUCTION: Breathlessness remains a highly prevalent and distressing symptom for many patients with progressive life-limiting illnesses. Evidence-based interventions for chronic breathlessness are limited, and there is an ongoing need for high-quality research into developing management strategies for optimal palliation of this complex symptom. Previous studies have suggested that selective serotonin reuptake inhibitors such as sertraline may have a role in reducing breathlessness. This paper presents the protocol for a large, adequately powered randomised study evaluating the use of sertraline for chronic breathlessness in people with progressive life-limiting illnesses. METHODS AND ANALYSIS: A total of 240 participants with modified Medical Research Council Dyspnoea Scale breathlessness of level 2 or higher will be randomised to receive either sertraline or placebo for 28 days in this multisite, double-blind study. The dose will be titrated up every 3 days to a maximum of 100 mg daily. The primary outcome will be to compare the efficacy of sertraline with placebo in relieving the intensity of worst breathlessness as assessed by a 0-100 mm Visual Analogue Scale. A number of other outcome measures and descriptors of breathlessness as well as caregiver assessments will also be recorded to ensure adequate analysis of participant breathlessness and to allow an economic analysis to be performed. Participants will also be given the option of continuing blinded treatment until either study data collection is complete or net benefit ceases. Appropriate statistical analysis of primary and secondary outcomes will be used to describe the wealth of data obtained. ETHICS AND DISSEMINATION: Ethics approval was obtained at all participating sites. Results of the study will be submitted for publication in peer-reviewed journals and the key findings presented at national and international conferences. TRIAL REGISTRATION NUMBER: ACTRN12610000464066.
dc.languageEnglish
dc.publisherBMJ PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleStudy protocol: a phase III randomised, double-blind, parallel arm, stratified, block randomised, placebo-controlled trial investigating the clinical effect and cost-effectiveness of sertraline for the palliative relief of breathlessness in people with chronic breathlessness
dc.typeJournal Article
dc.identifier.doi10.1136/bmjopen-2016-013177
melbourne.affiliation.departmentMedicine (Austin & Northern Health)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleBMJ Open
melbourne.source.volume6
melbourne.source.issue11
dc.rights.licenseCC BY-NC
melbourne.elementsid1126299
melbourne.contributor.authorMcDonald, Christine
dc.identifier.eissn2044-6055
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record